I thought the earnings were pretty decent. Obviously the market disagrees but I would love to hear your opinions of the earnings and today’s consequent drop in price.
02:35 AM EST, 02/10/2026 (MT Newswires) -- GSK (GSK.L) said China's Center for Drug Evaluation accepted for review its application for Arexvy as a vaccine in adults against respiratory syncytial virus-caused lower respiratory tract disease. According to a Tuesday filing, the British drugmaker is seeking approval in China for the use of the vaccine in adults aged at least 60 years. It supported the application with positive data from a phase 3 trial, and a regulatory decision is expected in 2027.
I thought the results today were decent, nice dividend growth for the upcoming and next year as well as the share buybacks. Market seems happy with the results what do you all think?
News on a new purchase for $GSK to strengthen its position in respiratory, immunology & inflammation offerings.
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-rapt-therapeutics-22-billion-2026-01-20/
GSK Q3 2025 Earnings in 5 Days: Execution vs. FX & IRA headwinds
When: Wed 29 Oct 2025, 07:00 GMT; management presentation follows (webcast link on GSK IR).
Street sees steady quarter with specialty meds leading; focus on whether FY25 stays “top-end” of guidance as FX and US policy headwinds bite.
4 Key Takeaways
• Consensus (Q3’25E): Turnover £8.24bn, Core EPS ~47.1p, Op. margin ~32.4%; WANS ~4,036m (buybacks reduce share count).
• FY25 Guidance (CER): Sales +3–5%, Core OP +6–8%, Core EPS +6–8%, management guiding toward the top end.
• Returns: FY25 dividend run-rate ~64p indicated earlier; £2bn buyback programme underway (three tranches completed/underway YTD).
• Watchpoints (Q3): FX −1% to −2% drag on sales; US IRA Part D redesign ~£400–500m FY headwind; step-up in SG&A to support launches; vaccine mix (Shingrix/Arexvy seasonality) and oncology momentum (Jemperli/Ojjaara).
⭐ Star Rating
• Dividend Strength: ⭐⭐⭐⭐☆
• Financial Health: ⭐⭐⭐⭐☆
• Growth/Pipeline: ⭐⭐⭐☆☆
• Valuation: ⭐⭐⭐☆☆
• Management/Execution: ⭐⭐⭐⭐☆
Overall: ⭐⭐⭐⭐☆ (4/5) Solid execution and shareholder returns; mind FX/IRA and vaccine mix into Q4.
If specialty meds + oncology keep comping strong and FX/IRA headwinds are contained, GSK can hold the top-end FY25 guide. I’ll be watching EPS leverage vs. SG&A step-up and any colour on Arexvy/Shingrix trajectory into Q4.
ccc1990
prieš 8 mėnesius
Lovely stuff
ContrarianCNT
prieš 8 mėnesius
What's happening guys?
Unable to check what's going on. Biggest daily pop I can remember on GSK.
Šiame puslapyje gali būti bendruomenės sukurto turinio, už kurį „Trading 212“ neatsako. Visada atlik savo tyrimą. „Trading 212“ teikia tik vykdymo paslaugą, bet neteikia investavimo konsultacijų ar portfelio valdymo paslaugų.
Turto kaupimas – įprotis. Automatizuokite jį naudodami Pies.
Investuok į paruoštus arba susikurk savo investicijų rinkinius, pasirinkdamas iš daugybės vertybinių popierių ir ETF
Sužinok daugiau
Sužinok daugiau
Žiūrėti vaizdo įrašą
Turėk net brangiausių akcijų, tokių kaip „Google“, „Amazon“ ir „Apple“
Žiūrėti vaizdo įrašą
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
„Euronext“ Paryžius
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Londono vertybinių popierių birža
„Euronext Lisbon“
Peržiūrėk visas prekybos priemones
Pagalba visą parą
29 sekundžių vidutinis atsako laikas
Pradėk kaupti turtą jau dabar
Prisijunk prie daugiau nei 5 mln. naudotojų
Atsisiųsti programėlę
Atidaryti sąskaitą
Atsisiųsk mobiliąją programėlę
Visi pateikti statistiniai duomenys yra globalūs. Klientų skaičius atspindi finansuotas sąskaitas.
Puiku
Įvertinta 4,6/5, remiantis 93 567 atsiliepimais apie
Trustpilot
Įvertinta 4,6/5, remiantis 93 567 atsiliepimais apie
Trustpilot
Pakviestas
Great
Immediate updates, easy to use and manage.
Pakviestas
Very easy to use
Very easy to use. Intuitive app and makes it straight forward to sit back and let your investment's do its work
Pakviestas
Ease of use
Easy to set up an account
Easy to transfer funds
Great interest rate
Great all round experience
Pakviestas
Easy to set up my account
Easy to set up my account easy to access balance and a very good rate in interest.
Pakviestas
easy to use platform
easy to use platform, love the ability to transfer cash isa funds into stocks and shares isa
Pakviestas
Simple and Informative platform
I wanted a platform which was offering great rates for my ISA, but discovered not only did this platform do that. It also gave me an insight into trading and world markets. It's quite simply brilliant.
Pakviestas
Great app that provides all my account…
Great app that provides all my account info at my fingertips
Pakviestas
Easy to use.
Easy to use.
Can view everything simply.
Just what I need.
Pakviestas
Good interest rate and can take the…
Good interest rate and can take the money out whenever I want.
Pakviestas
So easy
So easy! Makes investing a pleasure
Pakviestas
I’m novice and useless with technology…
I’m novice and useless with technology but I found this an easy site to navigate and to deal with.
Pakviestas
Nice app
Great app, very intuitive and simple to use. Gold standard.
Pakviestas
Very easy to use
Very easy to use. Very clear. And a joy to watch my savings rise
Pakviestas
Easy to use
Functional and easy to use and track my cash & stocks & shares isas
Pakviestas
Easy access to my account and how Easy…
Easy access to my account and how Easy it is to navigate the212 application.
Pakviestas
Simple and easy to use app
Simple and easy to use app. Ease of setting up recurring payments. Great for a beginner that has no prior knowledge or experience of investing.
Pakviestas
Easy and simple app
Easy and simple app, tells you daily your interest which I like and I get emails. The updating is really good.
Pakviestas
Very easy and highly recommend
Very easy and highly recommend. Straight forward to use and cost instructions on the fees and charges.
Pakviestas
Great way for your money to build
Just very pleased with the level of savings rate and steady build up.
Pakviestas
Cool app
User friendly mobile app that makes investing easy and funny. Fast navigation throughout the app. In a few clicks can see basically every information one might require.
Pateikiami keli teigiami mūsų klientų atsiliepimai
Mūsų apdovanojimai
Dažniausiai užduodami klausimai
Kokia yra GSK (GSK) akcijos kaina?
Dabartinė GSK (GSK) kaina yra 1 901,7 GBX.
Koks yra GSK52 savaičių maksimumas?
52 savaičių maksimumas GSK yra 2 281,7 GBX.
Koks yra GSK 52 savaičių žemiausias lygis?
52 savaičių žemiausias GSK kursas yra 1 318,7 GBX.
Koks yra GSK savaitės rezultatas?
Per pastarąją savaitę GSK kaina pasikeitė −0,85 %.
Koks yra GSK mėnesio našumas?
Per pastarąjį mėnesį GSK kaina pasikeitė 0,04 %.
Koks yra GSK 3 mėnesių rezultatas?
Per pastaruosius tris mėnesius GSK kaina pasikeitė −10,38 %.
Koks yra GSK 6 mėnesių rezultatas?
Per pastaruosius šešis mėnesius GSK kaina pasikeitė 3,75 %.
Koks yra GSKmetinis našumas?
Per pastaruosius metus GSK kaina pasikeitė 28,06 %.